HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Roivant Sciences (NASDAQ:ROIV) and maintains a $15 price target.
June 23, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reiterates Buy rating on Roivant Sciences and maintains a $15 price target.
The reiterated Buy rating and maintained $15 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Roivant Sciences. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100